Abstract:BackgroundThe combination of primary aldosteronism (PA) and alterations in plasma renin activity (PRA) is a leading cause of secondary hypertension. An accurate measurement of Renin Angiotensin-Aldosterone System (RAAS) pathway improves the recognition of symptoms related to stroke, coronary disease, heart failure and metabolic syndrome.MethodsPreviously, surrogate matrices have been used when demonstrating the analytical performance of LC-MS/MS clinical research methods for the measurement of aldosterone and angiotensin I. Here, we have developed an analytically sensitive and reliable analytical strategy for simultaneous measurement of Aldosterone and Angiotensin I in human matrices. In-house calibrators and quality control samples were prepared, containing varying ranges of both aldosterone (20-2000pg/mL; 55-5548pmol/L) and angiotensin 1 (0.6-240ng/mL; 0.46-185nmol/L). The samples were extracted using the OasisTM MAX 96-well μElution plate and then separated through the ACQUITYTM UPLCTM I-Class FL System using a XBridgeTM Premier Peptide BEHTM C18 Column, over a run time of 3 minutes. Samples were then injected to XevoTM TQ Absolute Mass Spectrometer, using both positive and negative acquisition modes. The downstream LC-MS/MS data analysis was performed using MassLynxTM MS Software. The analytical performance was demonstrated by extracting and quantifying two replicates of samples on two occasions per day over five separate days. Additionally, the stability of aldosterone and angiotensin I over the period of incubation (3-5hr) was evaluated, which is necessary when investigating the plasma renin activity in human Serum/Plasma samples.ResultsHigh reproducibility and repeatability were both determined, indicating total precision and repeatability (<15%CV) for both analytes and no significant changes were found in Aldosterone and Angiotensin I concentrations over 3-5hr of incubation. No significant system carryover ( 0.992 for all analyses at different incubation times. The analytical sensitivity of the clinical research method allows for precise quantification at 55 pmol/L for aldosterone and 0.46 nmol/L/hr for angiotensin I, with both analytes providing S/N (PtP) ≥10:1 and %RSD of <15% at these concentrations.ConclusionsAn analytically sensitive and selective clinical research method has been developed for the analysis of aldosterone and angiotensin I, using the Xevo TQ Absolute Mass Spectrometer. The Xevo TQ Absolute Mass Spectrometer enables the simultaneous analysis of physiologically low levels of aldosterone and plasma renin activity in human samples, (20pg/mL; 55pmol/L), (0.6ng/mL; 0.46nmol/h/L). A single test that improves instrument utilization, reduces cost, and allows the user to expand their existing test menu on the same platform has been established.

Comparison of ID-LC-MS/MS and Two CLIAs in Measuring Plasma Aldosterone

Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone

Development of a LC-MS/MS Method for Determination of Plasma Aldosterone and Its Performance Evaluation

An Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry Candidate Reference Measurement Procedure for Aldosterone Measurement in Human Plasma

Comparison of Plasma Aldosterone Measured by Chemiluminescence Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry in Screening Test for Primary Aldosteronism

A LC-MS/MS method for the simultaneous quantitative determination of aldosterone, its precursor 18-hydroxycorticosterone and its metabolite tetrahydroaldosterone in human urine

Comparison of a chemiluminescence immunoassay with LC-MS/MS in the determination of the plasma aldosterone concentration in patients with impaired renal function

A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay for simultaneous quantification of aldosterone, renin activity, and angiotensin II in human plasma

Comparison of Chemiluminescence Immunoassay with LC-MS/MS in the Determination of Plasma Aldosterone Concentration in Patients with Declined Renal Function

Insight into the status of plasma renin and aldosterone measurement: findings from 526 clinical laboratories in China

A-067 Simultaneous Measurement of Aldosterone and Plasma Renin Activity in Human Serum Using Liquid Chromatography Coupled to Tandem Mass Spectrometry for Clinical Research

PS-BPB04-9: DEVELOPMENT AND VALIDATION OF NEW METHOD TO MEASURE PLASMA ALDOSTERONE AND RENIN ACTIVITY USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETER (LC-MS/MS)

PS-C22-3: VALIDATION AND CLINICAL EVALUATION OF DIAGNOSTIC ABILITY OF NOVEL CHEMILUMINESCENT ENZYME IMMUNOASSAY OF PLASMA ALDOSTERONE CONCENTRATION.

Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood.

A novel LC-MS/MS-based assay for the simultaneous quantification of aldosterone-related steroids in human urine

New Screening Cutoff Values for Detection of Aldosteronoma Examined by Lc-ms/ms and A Newly Developed Non-competitive Chemiluminescent Enzyme Immunoassay

An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of aldosterone in human serum and plasma

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Based Assay for the Simultaneous Quantification of 18-Hydroxycorticosterone, 18-Hydroxycortisol and 18-Oxocortisol in Human Plasma

An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism

Diagnostic efficacy of chemiluminescence immunoassay versus radioimmunoassay in screening primary aldosteronism

Adrenal venous sampling criteria for chemiluminescent enzyme immunoassay as a preferable alternative to radioimmunoassay in primary aldosteronism.